All 10 Questions With Complete Rationales
Prefer to read straight through, or want to review after taking the quiz? Every question, the correct answer, and the reasoning behind it are laid out below.
Question 1
A patient with HFrEF (EF 35%) is on lisinopril and carvedilol. Which additional agent has been shown to reduce mortality and hospitalizations in HFrEF and should be considered?
A. Amlodipine B. Spironolactone (aldosterone antagonist) C. Diltiazem D. Hydralazine alone (without nitrates)
✅ Answer: B — Spironolactone (aldosterone antagonist)
Aldosterone antagonists (spironolactone, eplerenone) are guideline-directed medical therapy (GDMT) for HFrEF and reduce mortality and hospitalizations when added to ACEi/ARB and beta-blocker therapy. The RALES trial demonstrated mortality benefit for spironolactone in severe HF. Contraindicated if eGFR <30 mL/min or K+ >5.0 mEq/L. Amlodipine and diltiazem are not recommended in HFrEF. Hydralazine plus isosorbide dinitrate (not hydralazine alone) is an alternative for patients who cannot tolerate ACEi/ARB.
Question 2
A patient with hypertension and chronic kidney disease (CKD) with proteinuria has a blood pressure of 148/92 mmHg. Which antihypertensive class is the most appropriate first-line choice?
A. Calcium channel blocker (amlodipine) B. ACE inhibitor or ARB C. Beta-blocker (metoprolol) D. Thiazide diuretic (hydrochlorothiazide)
✅ Answer: B — ACE inhibitor or ARB
ACE inhibitors (e.g., lisinopril, ramipril) and ARBs (e.g., losartan, valsartan) are the preferred first-line antihypertensives in patients with CKD and proteinuria due to their renoprotective effects — reducing proteinuria and slowing CKD progression. They reduce intraglomerular pressure by dilating the efferent arteriole. Thiazides have reduced efficacy when eGFR <30. Do not combine ACEi + ARB (increases adverse effects without added benefit).
Question 3
A patient with atrial fibrillation has a CHA2DS2-VASc score of 3. Based on current ACC/AHA guidelines, which management approach is most appropriate?
A. Anticoagulation with a DOAC is recommended B. Aspirin alone is sufficient for stroke prevention C. Anticoagulation is not indicated at this score D. Rate control only — anticoagulation only for CHA2DS2-VASc ≥ 5
✅ Answer: A — Anticoagulation with a DOAC is recommended
CHA2DS2-VASc score of 3 indicates high stroke risk. ACC/AHA guidelines recommend anticoagulation for men with score ≥2 and women with score ≥3 (some guidelines: men ≥1, women ≥2). DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) are preferred over warfarin for non-valvular AF due to comparable or better efficacy with lower bleeding risk. Aspirin alone is NOT recommended for stroke prevention in AF — it is not effective and not a guideline-concordant alternative to anticoagulation.
Question 4
A patient presenting with STEMI is being treated emergently. Which antiplatelet combination is standard of care during PCI?
A. Aspirin alone B. Aspirin + a P2Y12 inhibitor (e.g., ticagrelor or prasugrel) C. Warfarin + aspirin D. Clopidogrel alone
✅ Answer: B — Aspirin + a P2Y12 inhibitor (e.g., ticagrelor or prasugrel)
Dual antiplatelet therapy (DAPT) with aspirin + a P2Y12 inhibitor is standard of care for STEMI, particularly when undergoing percutaneous coronary intervention (PCI). Ticagrelor and prasugrel are preferred P2Y12 inhibitors over clopidogrel for STEMI patients due to more rapid, consistent platelet inhibition. DAPT is continued for 12 months post-ACS in most patients. Prasugrel is contraindicated in patients with prior stroke/TIA.
Question 5
A patient with a 10-year ASCVD risk of 15% (high risk) and LDL-C of 130 mg/dL is being considered for statin therapy. Which statin intensity is appropriate?
A. Low-intensity statin (e.g., pravastatin 10 mg) B. Moderate-intensity statin (e.g., atorvastatin 10-20 mg) C. High-intensity statin (e.g., atorvastatin 40-80 mg or rosuvastatin 20-40 mg) D. No statin — lifestyle modification only at this risk level
✅ Answer: C — High-intensity statin (e.g., atorvastatin 40-80 mg or rosuvastatin 20-40 mg)
Per ACC/AHA Cholesterol Guidelines, patients with clinical ASCVD (secondary prevention) or 10-year ASCVD risk ≥7.5% (primary prevention, high or very high risk) benefit from high-intensity statin therapy, which reduces LDL-C by ≥50%. High-intensity statins include atorvastatin 40-80 mg and rosuvastatin 20-40 mg. A 15% 10-year risk is classified as high-risk, warranting high-intensity therapy. Lifestyle modifications are additive but not sufficient as monotherapy at this risk level.
Question 6
A patient is prescribed metoprolol succinate for heart failure. Which of the following beta-blockers is NOT approved for heart failure and should be avoided in HFrEF patients?
A. Carvedilol B. Metoprolol succinate (Toprol-XL) C. Bisoprolol D. Atenolol
✅ Answer: D — Atenolol
Only THREE beta-blockers have demonstrated mortality benefit in HFrEF and are approved for this indication: carvedilol, metoprolol succinate (Toprol-XL), and bisoprolol. Atenolol and other non-evidence-based beta-blockers should NOT be substituted — they have not demonstrated mortality benefit in HF trials. Metoprolol tartrate (the immediate-release formulation) is also not approved for HF. This is a high-frequency NAPLEX distinction question.
Question 7
A patient with newly diagnosed hypertension (BP 152/96 mmHg) has no other comorbidities. Which is the most appropriate first-line treatment per current guidelines?
A. Lifestyle modification alone (no medication for 6 months) B. Any of: thiazide diuretic, ACE inhibitor, ARB, or calcium channel blocker C. Beta-blocker as first-line monotherapy D. Combination of ACEi + ARB
✅ Answer: B — Any of: thiazide diuretic, ACE inhibitor, ARB, or calcium channel blocker
ACC/AHA 2017 guidelines recommend pharmacotherapy initiation at BP ≥130/80 mmHg for high-risk patients and ≥140/90 mmHg for all patients. For uncomplicated hypertension, four classes are equally acceptable as first-line: thiazide diuretics, ACE inhibitors, ARBs, or calcium channel blockers. Beta-blockers are now considered second-line for uncomplicated HTN without a compelling indication (HF, post-MI, angina). ACEi + ARB combination is contraindicated due to increased renal adverse effects.
Question 8
A patient with HFrEF is currently on lisinopril, carvedilol, spironolactone, and furosemide. Their physician wants to add sacubitril/valsartan (Entresto). What must be done before initiating sacubitril/valsartan?
A. Discontinue furosemide — it is contraindicated with sacubitril/valsartan B. Discontinue the ACE inhibitor at least 36 hours before starting sacubitril/valsartan C. Discontinue the beta-blocker at least 2 weeks before starting D. Discontinue spironolactone — aldosterone antagonists cannot be combined with ARNi
✅ Answer: B — Discontinue the ACE inhibitor at least 36 hours before starting sacubitril/valsartan
Sacubitril/valsartan (Entresto, an ARNi) contains valsartan (an ARB). It must NEVER be combined with an ACE inhibitor due to risk of severe angioedema. A washout period of at least 36 hours after the last ACE inhibitor dose is required before starting sacubitril/valsartan. The beta-blocker and spironolactone can be continued. This 36-hour washout is a critical safety fact frequently tested on the NAPLEX.
Question 9
A patient with atrial fibrillation is started on warfarin. What INR range is the target for stroke prevention in non-valvular AF?
A. 1.5 to 2.0 B. 2.0 to 3.0 C. 2.5 to 3.5 D. 3.0 to 4.0
✅ Answer: B — 2.0 to 3.0
The target INR for stroke prevention in non-valvular atrial fibrillation is 2.0 to 3.0. This range provides optimal benefit (stroke reduction) while minimizing bleeding risk. An INR of 2.5 to 3.5 is used for patients with mechanical prosthetic heart valves (especially mitral position). INR <2.0 provides insufficient protection; INR >3.0 significantly increases bleeding risk without additional stroke benefit.
Question 10
A patient with heart failure develops significant edema despite oral furosemide. The physician switches to IV furosemide. Which pharmacokinetic principle explains why IV furosemide is more effective than oral furosemide in decompensated heart failure?
A. IV furosemide has a longer half-life than oral furosemide B. Oral furosemide bioavailability decreases significantly in decompensated HF due to gut edema C. IV furosemide is metabolized differently, producing a more potent metabolite D. Oral furosemide is renally eliminated while IV is hepatically eliminated
✅ Answer: B — Oral furosemide bioavailability decreases significantly in decompensated HF due to gut edema
In decompensated heart failure, significant gut edema impairs GI absorption of oral medications. Oral furosemide bioavailability is normally 47-64% but decreases substantially in decompensated HF due to poor intestinal perfusion and edema of the gut wall. IV furosemide bypasses this absorption problem, achieving 100% bioavailability and predictable diuretic response. This is why IV diuresis is more effective during acute HF decompensation.
📌 How to use these
Answer each question before reading the rationale, and treat "right but unsure" as wrong. The rationale matters more than the answer — if you cannot explain why the other three options fail, you have not learned the rule yet. Ready for more? Work through the other free quizzes or the pharmacy law cheat sheet.